"We made considerable progress in 2022, including the filing and acceptance of two new INDs for our next generation CDK4/6 inhibitor and our first-in-class, highly selective SMARCA2 degrader. Our current clinical pipeline consists of four differentiated and internally discovered molecules that effectively target and block key oncogenic pathways in both hematological malignancies and solid tumors. Prelude’s highly productive internal discovery engine continues to deliver novel molecules across multiple therapeutic classes, including significant advances in our research efforts focused on identifying an orally available SMARCA2 degrader," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRLD:
- Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
- Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
- Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences